These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23846385)

  • 1. A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
    Ogawa Y; Ogura M; Suzuki T; Ando K; Uchida T; Shirasugi Y; Tobinai K; Lee JH; Kase M; Katsura K; Hotta T
    Int J Hematol; 2013 Aug; 98(2):164-70. PubMed ID: 23846385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
    Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.
    Hatake K; Ogura M; Takada K; Taniwaki M; Zhang F; Fujita T; Ando K
    Int J Hematol; 2017 Aug; 106(2):240-247. PubMed ID: 28421390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
    Coiffier B; Lepretre S; Pedersen LM; Gadeberg O; Fredriksen H; van Oers MH; Wooldridge J; Kloczko J; Holowiecki J; Hellmann A; Walewski J; Flensburg M; Petersen J; Robak T
    Blood; 2008 Feb; 111(3):1094-100. PubMed ID: 18003886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
    Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
    J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
    Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
    Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
    Nightingale G
    Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
    Österborg A; Wierda WG; Mayer J; Hess G; Hillmen P; Schetelig J; Schuh A; Smolej L; Beck C; Dreyfus B; Hellman A; Kozlowski P; Pfreundschuh M; Rizzi R; Spacek M; Phillips JL; Gupta IV; Williams V; Jewell RC; Nebot N; Lisby S; Dyer MJ
    Br J Haematol; 2015 Jul; 170(1):40-9. PubMed ID: 25825041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ujjani C; Ramzi P; Gehan E; Wang H; Wang Y; Cheson BD
    Leuk Lymphoma; 2015 Apr; 56(4):915-20. PubMed ID: 24925211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
    J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
    van Oers MH; Kuliczkowski K; Smolej L; Petrini M; Offner F; Grosicki S; Levin MD; Gupta I; Phillips J; Williams V; Manson S; Lisby S; Geisler C;
    Lancet Oncol; 2015 Oct; 16(13):1370-9. PubMed ID: 26377300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
    Ishizawa K; Fukuhara N; Nakaseko C; Chiba S; Ogura M; Okamoto A; Sunaga Y; Tobinai K
    Jpn J Clin Oncol; 2017 Jan; 47(1):54-60. PubMed ID: 28122892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.
    Davids MS; Kuss BJ; Hillmen P; Montillo M; Moreno C; Essell J; Lamanna N; Nagy Z; Tam CS; Stilgenbauer S; Ghia P; Delgado J; Lustgarten S; Weaver DT; Youssoufian H; Jäger U
    Clin Cancer Res; 2020 May; 26(9):2096-2103. PubMed ID: 31964785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
    Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
    Korycka-Wołowiec A; Wołowiec D; Robak T
    Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.